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Summary
Factoi V Leiden and factor IIG20210A mutations are two fiequent
genetic nsk factors mvolved in venous thromboembolism (VTE) The
goal of this pooled analysis of 8 case-control studies, comprismg a total
of 2310 cases and 3204 controls, was to precisely estimate the nsk of
VTE m patients bearmg both mutations (double heterozygotes) Odds
ratios for VTE were 4 9 (95% CI, 41-59) foi the factor V Leiden and
3 8 (3 0-4 9) foi the factor IIG20210A mutation Fifty-one cases (2 2%)
and none of the controls were double heterozygotes The odds ratio for
venous thrombosis in double heteiozygotes was 200 (11 1-361)
Twelve percent of patients heteiozygous for factoi V Leiden were also
heterozygous for factor II G20210A and conversely 23% of patients
heterozygous for factor IIG20210A were also heterozygous for factor
V Leiden Fuithermore, m this large population we analyzed the effect
of oral contraceptive (OC) m women carrymg one of these mutations
Odds ratio foi VTE associated with OC was 2 29 (l 72-3 04) In factor
V Leiden carners usmg OC, the odds ratio for VTE was 1025
(5 69-18 45) The odds ratio of the association of factor II mutation and
OC use was 7 14 (3 39-15 04) Fmally, we also confirmed that the
frequency of factor V Leiden was lowei in patients with pulmonary
embohsm than in patients with deep vem thrombosis without PE (odds
" The study group foi pooled-analysis in venous thiomboembolism
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ratio 069) Conversely, factor II G20210A mutation was equally
balanced m both patient groups
Introduction
Venous thromboembolism (VTE) is a common disorder with a
yearly mcidence of about one in 1000 subjects m developed countnes
(1) Genetic nsk factors responsible for thiombophiha have been
recogmzed to have an important role in Caucasian populations (review
m 2) Fuithermore, it has become apparent durmg the last few years
that the development of venous thrombosis is multifactoiial, and that
acquired nsk factors mteractmg with genes or gene-gene mteractions
are mvolved in a large proportion of patients (3-5) Factor V Leiden
(FV G1691A) and prothrombm G20210A mutations are the most
frequent genetic nsk factors mvolved in deep vein thrombosis (DVT)
and/οι pulmonary embohsm (PE) (6-8) Among Caucasians factor V
Leiden frequency vanes between 2 and 15%, and is found m 15 to 25%
of unselected patients with DVT (9-11) Heterozygosity for factor V
Leiden mcreases the thrombotic nsk three- to eightfold, and the nsk
in homozygotes was estimated to be mcreased 80-fold (12) The
prothrombm G20210A mutation is found m 1-3% of Caucasians
(13) and m 6-16% of patients with unselected DVT (8, 14-21)
These two mutations are common m Caucasian populations with
venous thrombosis, thus lepiesentmg a good model for the study of
gene-gene mteraction
Due to the relatively low prevalence of these polymorphisms in the
general population (5% foi the factor V Leiden mutation and 2% for the
prothrombm G20210A), the expected prevalence of double hetero-
zygotes for the factor V Leiden mutation and the prothrombm mutation
is about l per 1000 Very large senes are thus necessary to study
gene-gene mteraction in order to give rehable Information concernmg
the thrombotic nsk estimate In the present study, we pooled the indi-
vidual data of 8 case-control studies to evaluate the nsk associated with















with a first DVT
consecutive outpatients
with DVT
f irst or recurrent DVT or PE referred
for thrombophiha screening
first or recurrent DVT or PE
first or recurrent DVT or PE referred
to a thrombosis center
first or recurrent DVT
first or recurrent DVT or PE
first or recurrent DVT or PE
/
n controls
474 population controls, age
and sex-matched
281 healthy controls
161 healthy plasma donors
1 30 staff of the hospital (student,
lab workers and doctors)
850 healthy controls
559 population controls, patients
with unconftrmed DVT, staff
35 1 blood donors and hospital staff
398 healthy controls age- and
sex- matched
3204
Table l Number and type
of recruitment for cascs



















































Table 2 Prevalence (%) of the fattor V Leiden
(G 1691 A) and the prothrombm 2021OA allele m each
center
Table 3 Charactenstics oi cases and contiols (VTE venous thromboem
bolism, DVT deep vem thrombosis, PE pulmonary embolism) Y p < 0 0 1
Female (n,%)
Male (n,%)
Mean age of the population
Mean age at the first event
% with first episode of VTE
% with isolated DVT
% with isolated PE
% with DVT+PE






















effect of oral contraceptive use on the nsk for VTE in women carrymg
one of the thrombophihc mutations with that observed in non-cainers
(22) Finally we evaluated m this large population the nsk for pul-
monary embolism associated with the factor V Leiden and prothrombm
G20210AmuUtions(23)
Methods
The mdividual data of eight case contiol studies fiom six different countnes
that have genotyped patients and controls for the factor V Leiden and
prothrombm G20210A mutations were pooled The ongmating cenlre, the
number of cases and controls, and the recruitment cntena ior conlrols m each
study are hsted in Table l Seven out of the 8 centres were m Europe, from
Scandmavia to Italy, and only one mcludes subjects trom South America
(Campinas, Bra/il) Except for this last study all the other centres mcluded
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Table 4 Genotypes of the
factorVG1691A(tactorV
Leiden) und factor II
G20210A mutations foi




Cases [n(%)] 1869(814%) 398(173%) 30(13%)





mamly Caucasian mdividuals Bach of these studies has been previously
published elsewhere (8, 14 20) Cases mcluded patients who had had at least
one objectively confirmed episode of VTE Foi controls, vanous healthy
mdividuals were lecruited and ranged ftom populations that were age and sex
matched to blood donors 01 hospital staff The prevalencc of factoi V Leiden
and factor II 20210A allele m cases and controls, in each centre, is given m
Table 2
Charactenstics of cases and controls foi the pooled population are given m
Table 3 The cases and controls weie well matüied for age, but there was a
sigmficant difference m the sex-iatio, with 57% of wonien among cases and
52% among controls (p <001) Infoimalion on recunence of VTE was not
available m 21% of cases Information concernmg the type of venous thiombo
sis (PE and/οι DVT) was not available for 22% of cases
All centres except two used a süategy for the detection of the factor V
Leiden mutation and the prothrombm 20210 allele similar to the onginally
descnbed methods (7, 8) Factor V Leiden was determmed by SSCP (smgle
Strand conformation polymorphism) in Napoli (24), and in Paris factor V
Leiden and piothrombin mutations were determmed äs previously descnbed
(20) Each centre reported that then molecular biology protocols were robust
Statifitical Analyns
Patient chaiactenslics were presented äs means with Standard deviations for
contmuous variables and counts and percentages for categoncal vanables
Groups were detmed according to the piesence of factor V Leiden (G1691 A)
and piothrombin G20210A mutations, and use of oial contraception The event
was defined äs the occurrence of DVT and/or PE Compansons between groups
wete caiiied out usmg the unpaned Student t test or Mann-Whitney U-test for
contmuous vaiiables according to theirdistnbution and a Chi squareorFisher's
exact test for categoncal variables Hardy Weinberg equihbrmm was tested
for by a Chi-square test with I D F , sepaiately in cases and controls from the
different recruitment centres Allele frequencies were calculated from the
genotype frequencies, and differences between the cases and controls were
identified by means of a Chi-square test ( I D F )
The results fiom each study were summanzed m two by two tables for each
Potential nsk factor for VTE Carriers for mutations of factor V G1691A and
prothrombm G20210A weie heterozygous or homozygous for the mutation As
was pieviously done for the meta analysis of therapeutic tnals (25) and äs
there was no reason to favour a particular effect model, we used vanous
methods based on both fixed and random effect models - that is, the combmed
loganthm of the odds tatio, Mantel-Haenszel, Cochran, Peto, and percentage
difference (both fixed and random effects models) Because the results obtamed
from the different methods weie similar, only the odds ratios calculated with
Peto's method were given with the correspondmg 95% confidence mtervals
When no events were reported for a group a value of 0 25 was automatically
attnbuted for the calculation of the odds ratio Association and heterogeneity
tests were pei formed for each analysis (26) Heterogeneity was considered to be
present when the p value from the homogeneity test was less than or equal to
0 05 Whenever apphcable the causes of heterogeneity were sought A p value
of 0 01 or less from an association test was taken to be sigmficant
Statistics were computed with Statview 5 statistical Software, SAS, Cary,
NC, USA The meta-analysis was c-onducted with EasyMA (a program for




A total of 2310 patients and 3204 controls were analyzed Data
concernmg the factor V genotype were lackmg for 29 subjects (13
Λ\3
Fig l Odds ratios for venous thromboembohc dis
ease associated with the presence of both factor II
G20210A and factor V G169|A mutations Total odds
ratio was computed with Peto's method (test of heleio
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^ OR = 3.8 (3.0 - 4.9)
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Fig. 2 Odds ratios for venous thromboembolic dis-
ease associated with factor II G20210A mutation.
Total odds ratio was computed with Peto's method (lest
of heterogeneity, p = 0.83, Q Cochran lest)
cases and 16 controls) and concerning prothrombin in 11 subjects (6
cases and 5 controls). Among the cases, 428 (18.6%) carriers of the
factor V Leiden mutation were identified (including 30 homozygotes),
and 216 (9.4%) carriers of the prothrombin G20210A mutation (inclu-
ding 5 homozygotes) were identified (Table 4). Among the controls,
144 (4.5%) subjects carried the factor V Leiden mutation (including 4
homozygotes), and 93 (2.9%) carried the prothrombin G20210A muta-
tion. Odds ratios associated with venous thrombosis for the factor V
Leiden and prothrombin G20210A mutations are indicated for each
centre in Figs. l and 2 respectively. For the whole population, odds
ratios for venous thrombosis associated with the factor V Leiden and
the prothrombin mutations were 4.9 (95% CI; 4.l -5.9) and 3.8 (95% CI;
3.0-4.9), respectively.
Thirty cases were homozygous for the factor V Leiden mutation
(1.3%) compared to 4 controls (0.13%). The odds ratio for venous
thromboembolism associated with homozygosity for factor V Leiden
was 9.85 (95% CI; 4.83-20.09). We were unable to estimate the risk of
homozygous prothrombin G20210A mutation, äs 5 cases (found in a
single center) and no controls were too few to allow a meaningful
estimation to be performed.
Combined Defect (Double Heterozygote)
Fifty-one cases (2.21%) and none of the controls were double
heterozygotes. The odds ratio for venous thrombosis in carriers of both
the factor V Leiden and the prothrombin mutations was 20.0 (CI 95%;
11.1-36.1) (Fig. 3). Among the 398 cases heterozygous for factor V
Leiden, 48 (12%) were also heterozygous for prothrombin G20210A.
Conversely, among the 211 cases heterozygous for prothrombin
G20210A, 48 (23%) were also heterozygous for factor V Leiden. Two
cases homozygous for factor V Leiden were also heterozygous for
prothrombin G20210A (6.6% of the 30 FV Leiden homozygotes). One
among 5 homozygotes for prothrombin G20210A was also hetero-
zygous for factor V Leiden.
In double heterozygous cases, the age of the first episode of VTE
was significantly younger than the remaining cases (34.7 vs 40.6 years;
p <0.01). The odds ratio for occurrence of VTE below the median of
age (44 years) was 2.21 (95% CI; 1.22-3.98) for carriers of both
mutations but was not increased for each mutation alone (odds ratios












4L· OR = 20.0 (11.1 -36.1)
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Fig. 3 Odds ratios for venous thromboembolic dis-
ease associated with factijr V G169JA mutation. Total
odds ratio was computed with Peto's method (test of
helerogeneity, p = 0.07, Q Cochran test)
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Table 5 Odds ratios for venous thiomboembohsm
associated with oral contraceptive, factor V Leiden
mutation and/οι factor II G20210A in women aged 15
to 49 years in the 3 case control studies m which Infor-
mation was available (517 cases and 518 controls)
Oral Factor V Factor H p
contraceptive Leiden G20210A OR (95% CI) heterogeneity
1 (Ref)
+ - 2 29 (1 72 3 04)
+ 5 88 (3 52 9 82)
+ 321(144-715)
+ + 14 67 (3 47 62 03)
+ + - 1025(5691845)
+ - -i- 7 14 (3 39 15 04)









Information concernmg the use of mal contraceptives in cases and
controls was fully available in 3 centres (Leiden, Milano, Paris) The
total number of women, aged 15 to 49 years, was 1035 (517 cases and
518 contiols) Fifty two per cent (270/517) of the cases and 30%
(153/518) of the controls used oral contraceptives For this subset of the
whole female population, the odds ratio for VTE associated with oral
contraceptive use was 2 29 (95% CI l 72-3 04) (Table 5) In factor V
Leiden carriers usmg oral contiaceptive, the odds ratio for VTE
was 10 25 (95% CI, 5 69-18 45) The odds ratio for the association of
the prothrombin G20210A mutation and oral contraceptive use
was shghtly lower [7 14 (3 39-15 04)] Double heterozygous women
who used oral contraceptives had an odds latio of 16 97 (95% CI
3 95-72 80)
Pulmonary Embohsm
In order to determme if the prevalence of the mutations were
equally balanced between PE and DVT cases, we analyzed genotype
prevalence m patients with each climcal entity The frequency of factor
V Leiden was lower in patients with symptomatic PE (isolated or
associated with DVT) than m patients who had DVT without sympto-
matic PE (14 7% and 20 0% respectively, OR 0 69,95% CI 0 51-0 92)
(Table 6) Conversely, the carriers of the prothiombin G20210A
mutation or with both mutations were equally distnbuted among
patients with either DVT or symptomatic PE
Discussion
The understandmg of the causes of VTE, a multifactonal disease
due to a combination of genetic and envuonmental factors, is a major
goal in order to achieve better prevention and treatment of the disease
The most efficient design for genetic studies of multifactonal diseases
is the companson of allele frequencies in unrelated cases and controls
in studies of at least 1000 cases and controls or large family studies
(27) To study gene-gene or gene-environmenl mteractions, larger
populations are required to achieve a sufficient number of cases and
controls who combine 2 or more nsk iactors For factor V Leiden and
prothrombin G20210A numerous studies have given concordant results
concernmg the nsk associated with each mutation, but the odds ratio in
double heterozygotes was unknown Several studies have pomted out
an overrepresentation of cameis of both mutations m patients with
VTE, but due to lack of power none of them was able to precisely
estimate the nsk (17-20,28-30) Most of them have shown that factor V
Leiden carneis who had a VTE episode were more frequently carriers
of the prothrombin G20210A mutation, but m most cases the associa-
tion was absent in controls
In this pooled analysis of 2310 cases and 3204 controls the odds
ratio for VTE m carriers of FV Leiden was 4 9 (95% CI 4 l 5 9) The
odds ratio m carriers of the prothrombin 2021OA allele was 3 8 (95%
CI 3 0-4 9) The estimated prevalence of carriers of both mutations m
control Caucasian populations is l 1000 Thus, we expected to find 3
double heterozygotes among the 3204 controls but none was observed
In the present study 51 of the 2310 cases (2 2%) canied both mutations
Table 6 Prevalence and
OR (95% CI) for symp-
tomatic PE (with or with-
out DVT) by reference to
isolated DVT associated
with factor V, facloi II and
association of the two mu
tations(N= 1791 patients)
Factor V Factor II FV GG FV GA or AA
GG GA or AA GG GA or AA + FII GG + FH GA or AA
PE or PE+DVT [n(%)J
Isolated DVT [n(%)]
396 (85 3) 68 (14 7)
1062(800) 265(200)
OR (95 % CI) for PE associated o 69 (0 51 0 92)
with mutation





453 (97 6) 11 (2 4)
1292(974) 35(26)




Double heterozygosity was associated with an odds ratio for venous
thrombosis of 200 (95% CI, 1 1 1 36 1) The 22% prevalence of
double heterozygotes m patients with venous thromboembohsm refmes
the estimation of l to 5%, found m smaller populations (31-33)
Compared to the odds ratios obtamed for camers of either the factor V
Leiden mutation or the prothrombm G20210A mutation alone, a
complete multiphcative effect of the association was observed (synergy
index l 07) (5) If double heterozygotes are relatively mfrequent, it
should be noted that 12% of patients with the factor V Leiden mutation
also bear the prothrombm 20210A allele and conversely that 23% of
patients heterozygous foi the prothrombm G20210A mutation also
carry the factor V Leiden mutation Furthermore, double heterozygous
patients had thrombosis at a sigmftcantly younger age compared to
other cases
We also took advantage of this large senes to estimate the odds ratio
associated with homozygosity for each mutation The odds ratio for
venous thromboembohsm associated with homozygosity for factor V
Leiden was lower than the estimation of an mcreased nsk of 80-fold
found by Rosendaal et al (12) In this last study, 8 homozygotes were
found among 471 patients (l 7%) and none in 474 age- and sex
matched controls leadmg to an estimation of the odds ratio of 79 4 with
a broad 95% confidence mterval (22-289) The present results, based on
a much larger population, estimate a 10-fold mcreased nsk for factor V
Leiden homozygotes (OR 9 85,95% CI 4 83-20 09) However, due to
the very low prevalence in the normal population, we cannot consider
this estimation äs fully rehable Nevertheless, it confirms that if
homozygotes for factor V Leiden have an undoubtedly relatively high
nsk of thrombosis, they can also remam asymptomatic even after their
sixties (34) We have no clear explanation for this discrepancy, but it
may be due to the difficulty to precisely estimate a nsk when none of
the controls carnes the nsk factor (35)
The nsk of oral contraceptive use alone or associated with the factor
V Leiden and prothrombm G20210A mutations was analyzed by
poolmg the data from three studies (Leiden, Milano, Paris) The odds
ratio for venous thromboembohsm associated with oral contraceptive
use was 2 29 (95% CI l 72-3 04) This is m accordance with the less
than 3 fold mcrease found m a recent review (36), but shghtly lower
than the 3 to 4-fold mcreased nsk found m the Leiden Thrombophiha
Study (22,37) Smce controls were very well matched in this last study
our result is likely to be an underestimate Nevertheless, the ränge of the
odds ratio that we found clearly overlaps the data found m previous
studies, givmg support to the coherence of our estimation mvolvmg a
much larger population The odds ratios for the association of oral
contraceptive use with the factor V Leiden or the prothrombm 20210A
mutation were 10 25 (95% CI 5 69 18 45) and 7 14 (95% CI 3 39 to
15 04), lespectively (Table 5) The jomt relative nsks are clearly highei
than the effect of each nsk factor alone, and exceed the sum of the
relative nsks mdicatmg a supra-additive effect (5) In other words, the
relative nsk caused by the use of oral contraceptives is of similar
magmtude m camers and non-carners for both of these frequent muta
tions, but the absolute nsk is much higher Due to the small number of
women bearmg both mutations and usmg oral contraceptives the nsk
estimation is less precise (OR 16 97,95% CI 3 95 72 80)
We confirmed that factor V Leiden is more strongly associated with
the occurrence of deep vein thrombosis than with pulmonary embohsm
(23,38-41), and conversely that the prothrombm G20210A mutation is
evenly distnbuted m patients with deep vein thrombosis or pulmonary
embolism These data are based on 78% of the whole study population
and on the symptomatic events presented by each patient We cannot
exclude that some patients with symptomatic DVT had asymptomatic
PE and vice versa Due to the fact that some centres mcluded only
patients with DVT, the number of patients with eithei isolated PE or PE
associated with DVT is only 25% of the whole population This could
mduce an important bias Nevertheless, m a large cohort of unselected
patients with deep vein thrombosis or pulmonary embohsm, we found
a different prevalence of the factor V Leiden and prothrombm
G20210A mutations This suggests that different patterns of venous
thrombosis are not always associated with similar relative nsks to
specific nsk factors (42) Furthermore, a lower frequency of proximal
DVT (most likely associated with PE) m patients with the factor V
Leiden mutation, compared to non-carners, was recently demonstrated
(43)
Rehable Information on the role of geneüc polymorphisms m ve
nous thromboembohsm will help to clanfy disease mechamsms A
problem with estimatmg the genetic nsk for venous thromboembohsm
is either that the effect of any common polymorphism at a smgle locus
is only moderate, or that the nsk of the mterrelation of 2 or more
polymorphisms is high but difficult to assess rehably when too few
cases and controls are mvolved Such relatively small case-control
strategies are still not able to analyze actual synergistic effect, i e that
two smgle polymorphisms are not individually nsk factors for venous
thromboembohsm, but that their jomt effect m the same mdividual
mcreases the nsk of the disease In the absence of studies of sufficient
size, meta analysis can help to refine the estimation of the nsk (44)
However, because more extremely positive results are more likely to be
pubhshed, the combmation of pubhshed studies may tend to overes
timate the strength of any association Also, meta analysis of case-
control studies present particular challenges because of inneren! bias
such äs differences m recruitment and study designs In the present
study, one centre (Campinas, Brazil) had a much lower mcidence of
the factor V Leiden mutation compared to the other centres (Table 2)
Nevertheless, the odds ratios for the pooled population given m Figs l
to 3 were not sigmficantly modified after exclusion of the Brazihan
population (data not shown) The fact that we pooled mdividual data
with very few missmg genotypes (0 5% for the factor V Leiden muta-
tion and 0 2% for the prothrombm G20210A mutation) strengthens the
value of our results Despite the large number of subjects analyzed, we
cannot consider the estimation of the thrombotic nsk m double hetero-
zygotes fully rehable due to the absence of such a genotype among the
3204 controls If one considers that it is relevant to study gene gene or
gene environment mteractions m venous thromboembohsm, studies
with more than 5000 cases and 5000 controls may well be needed and
will be difficult to conduct m a smgle centre Large multicentre tnals m
well defmed populations, mcludmg if possible a follow-up after a first
event, would clanfy the role and the mteractions of the more numerous
genetic or non genetic nsk factors for VTE
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